Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Excedrin

This article was originally published in The Tan Sheet

Executive Summary

Bristol-Myers Squibb launches TV ad in July touting Extra Strength Excedrin as "the headache medicine." Created by New York- based Bozell, the spot maintains that medical research shows that Excedrin is "better" for headaches. The ad features a woman advising consumers that they should not give up McNell's Tylenol for fever, but suggests that headache sufferers should take Excedrin. A Sept. 12 FSI also emphasizes the product's "headache medicine" theme. BMS recently reassigned advertising for three of its Excedrin products from DDB Needham, New York, with Bozell picking up the Extra Strength Excedrin and Aspirin-Free Excedrin accounts ("The Tan Sheet" July 12, In Brief).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS081921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel